Tobacco, electronic nicotine delivery system, nicotine replacement therapy, and cannabinoid use during pregnancy: A descriptive cross-sectional survey
PLOS One · 2025
DOI: 10.1371/journal.pone.0332961 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift PLOS One, 2025. Verfasst von Sreemanjari Kandhasamy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Electronic Nicotine Delivery Systems, Smoking Cessation, Cannabinoids, Tobacco Use Cessation Devices. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Investigator Initiated Clinical Trial (IICT) grant from the Swiss National Science Foundation (SNSF), Swiss Tobacco Prevention Fund (TPF), Swiss Cancer Research (SCR).
Abstract (Originalsprache)
Introduction
Tobacco smoking is associated with adverse health outcomes for both pregnant women and their offspring. Smoking cessation counseling is an effective method to help women quit smoking. Developing a targeted smoking cessation intervention could benefit those who struggle to quit tobacco and potentially reduce the harm due to any co-occurring tobacco use. Assessing the prevalence of tobacco, electronic nicotine delivery systems (ENDS), nicotine replacement therapy (NRT), and cannabinoid use in pregnancy is key to developing such interventions. Thus, we aimed to assess the prevalence and patterns of tobacco, ENDS, NRT, and cannabinoid use in pregnancy. We further aimed to assess the prevalence of smoking cessation counseling intervention. Materials and methods We conducted a cross-sectional survey among pregnant women attending regular clinical visits at Spitalzentrum Biel between February and May 2023 (n = 262). Frequency and proportion along with 95% confidence intervals (CI) were reported for tobacco, ENDS, NRT, and cannabinoid use in pregnancy.
Results
Tobacco use was reported among 7.6% (20/262, 95% CI: 4.2%−11.1%) of the included pregnant women. Tobacco cigarettes (conventional or roll-on) were used by 7.3% (19/262, 95% CI: 3.8%−10.7%) of the surveyed pregnant women, with 0.8% (2/262, 95% CI: 0.0%−3.4%) of them reporting use of cigarettes along with ENDS and 0.4% (1/262, 95% CI: 0.0%−3.8%) reporting use of the cigarettes with NRT. Cannabinoid use was reported by 3.8% (10/262, 95% CI: 1.1%−7.0%) of pregnant women and all of them used products with Cannabidiol (CBD) only. Additionally, only 25% (5/20, 95% CI: 10.0%−48.3%) of tobacco users had received smoking cessation counseling intervention.
Conclusion
The estimated prevalence of tobacco, ENDS, NRT, and cannabinoid use among the pregnant women in this survey was 7.6%, 0.8%, 0.4%, and 3.8% respectively. However, among tobacco users, only one-fourth received smoking cessation counseling intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
- Graduate School of Health Sciences, University of Bern, Bern, Switzerland.
- Institute of Psychology, University of Lausanne, Lausanne, Switzerland.
- Department of Obstetrics and Gynecology, Centre Hospitalier Bienne, Bienne, Switzerland.
- Materno-Fetal and Obstetrics Research Unit, Department "Woman-Mother-Child", Lausanne University Hospital, Lausanne, Switzerland.
- Center of Primary Care and Public Health (UNISANTÉ), University of Lausanne, Lausanne, Switzerland.
ORCID-Profile: Sreemanjari Kandhasamy, Stephen P Jenkinson, Anna Schoeni
Förderung
- Investigator Initiated Clinical Trial (IICT) grant from the Swiss National Science Foundation (SNSF)
- Swiss Tobacco Prevention Fund (TPF)
- Swiss Cancer Research (SCR)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Kandhasamy, S., Baggio, S., Mathis, J., Mattmann, Y., Maisonneuve, E., Auer, R., Panchaud, A., Jenkinson, S. P., & Schoeni, A. (2025). Tobacco, electronic nicotine delivery system, nicotine replacement therapy, and cannabinoid use during pregnancy: A descriptive cross-sectional survey. PLOS One. https://doi.org/10.1371/journal.pone.0332961
Vancouver
Kandhasamy S, Baggio S, Mathis J, Mattmann Y, Maisonneuve E, Auer R, et al. Tobacco, electronic nicotine delivery system, nicotine replacement therapy, and cannabinoid use during pregnancy: A descriptive cross-sectional survey. PLOS One. 2025. doi:10.1371/journal.pone.0332961
BibTeX
@article{Kandhasamy2025,
author = {Kandhasamy, Sreemanjari and Baggio, Stéphanie and Mathis, Jérôme and Mattmann, Yolanda and Maisonneuve, Emeline and Auer, Reto and Panchaud, Alice and Jenkinson, Stephen P and Schoeni, Anna},
title = {Tobacco, electronic nicotine delivery system, nicotine replacement therapy, and cannabinoid use during pregnancy: A descriptive cross-sectional survey},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0332961}
}
EUVIMED